Naz Chaudary

Transport characteristics of HL-1 cells: a new model for the study of adenosine physiology in cardiomyocytes.

Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1.

The adenosine transporter, mENT1, is a target for adenosine receptor signaling and protein kinase Cepsilon in hypoxic and pharmacological preconditioning in the mouse cardiomyocyte cell line, HL-1.

Hypoxia and metastasis.

Hypoxia and metastasis in breast cancer.

The tumor microenvironment and metastatic disease.

Increased expression of metastasis-related genes in hypoxic cells sorted from cervical and lymph nodal xenograft tumors.

Characterization of mammalian equilibrative nucleoside transporters (ENTs) by mass spectrometry.

Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer.

Orthotopic xenograft model of cervical cancer for studying microenvironmental effects on metastasis formation and response to drug treatment.

Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation.

Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition.

Hypoxia and metastasis in an orthotopic cervix cancer xenograft model.

Hypoxic activation of the PERK/eIF2α arm of the unfolded protein response promotes metastasis through induction of LAMP3.

Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx).

Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice.

Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry.

Establishment of orthotopic primary cervix cancer xenografts.

The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer.

Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells.

Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.